Compare BNR & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNR | CIF |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.7M | 31.1M |
| IPO Year | 2020 | N/A |
| Metric | BNR | CIF |
|---|---|---|
| Price | $19.75 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 73.4K | 43.9K |
| Earning Date | 11-20-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,749,382.00 | N/A |
| Revenue This Year | $136.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.56 | N/A |
| 52 Week Low | $2.18 | $1.47 |
| 52 Week High | $23.59 | $1.77 |
| Indicator | BNR | CIF |
|---|---|---|
| Relative Strength Index (RSI) | 61.06 | 49.20 |
| Support Level | $15.71 | $1.68 |
| Resistance Level | $18.42 | $1.76 |
| Average True Range (ATR) | 2.16 | 0.02 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 63.65 | 33.33 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.